These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 1415366)

  • 21. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH; Holzer H; Mayer GJ;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
    De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
    Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
    G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study.
    Branger B; Vécina F; Zabadani B; Balducchi JP; Fourcade J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():36-9. PubMed ID: 8524492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose subcutaneous recombinant erythropoietin in children with chronic renal failure. Australian and New Zealand Paediatric Nephrology Association.
    Burke JR
    Pediatr Nephrol; 1995 Oct; 9(5):558-61. PubMed ID: 8580009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
    Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
    Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.
    Winearls CG; Oliver DO; Pippard MJ; Reid C; Downing MR; Cotes PM
    Lancet; 1986 Nov; 2(8517):1175-8. PubMed ID: 2877323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
    Bommer J; Asmus G; Wenning M; Bommer G
    Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose escalation induces tolerance to side-effects of erythropoietin in a patient with dialysis anaemia: case report.
    Ohira N; Takasugi K; Takasugi N; Yorioka N; Ito T; Kushihata S; Takemasa A
    J Int Med Res; 1998; 26(2):102-5. PubMed ID: 9602990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.
    Locatelli F; Olivares J; Walker R; Wilkie M; Jenkins B; Dewey C; Gray SJ;
    Kidney Int; 2001 Aug; 60(2):741-7. PubMed ID: 11473657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
    Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
    S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study.
    Cheng IK; Cy C; Chan MK; Yu L; Fang GX; Wei D
    Clin Nephrol; 1991 May; 35(5):207-12. PubMed ID: 1855328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
    Macdougall IC
    Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.